Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Short-term Investments (2019 - 2025)

aTYR PHARMA's Short-term Investments history spans 7 years, with the latest figure at $67.9 million for Q4 2025.

  • For Q4 2025, Short-term Investments rose 11.26% year-over-year to $67.9 million; the TTM value through Dec 2025 reached $67.9 million, up 11.26%, while the annual FY2025 figure was $67.9 million, 11.26% up from the prior year.
  • Short-term Investments reached $67.9 million in Q4 2025 per ATYR's latest filing, down from $84.1 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $105.6 million in Q4 2021 to a low of $38.0 million in Q1 2021.
  • Average Short-term Investments over 5 years is $71.6 million, with a median of $69.8 million recorded in 2024.
  • Peak YoY movement for Short-term Investments: soared 616.39% in 2021, then crashed 46.8% in 2022.
  • A 5-year view of Short-term Investments shows it stood at $105.6 million in 2021, then plummeted by 46.8% to $56.2 million in 2022, then skyrocketed by 34.64% to $75.6 million in 2023, then fell by 19.24% to $61.1 million in 2024, then increased by 11.26% to $67.9 million in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Short-term Investments are $67.9 million (Q4 2025), $84.1 million (Q3 2025), and $63.1 million (Q2 2025).